Publishing Your Invention: When Not to Commercialize

Siert Bruins Siert Bruins is the author of this webpage
Publishing your invention instead of commercializing is also a genuine choice

Not every invention has to lead to a company, a product, or a deal. In some cases, the most realistic outcome is that nothing happens — at least not in a commercial sense. Projects stall, priorities shift, people move on, or the timing is simply not right.

As a researcher or inventor, you may also make a deliberate choice. You might prefer to focus on science, publish your work, and build an academic career rather than getting involved in business. That is a valid path, and for many people, it is the right one.

But “doing nothing” is rarely as simple as it sounds. Once an invention exists, it can still trigger decisions around intellectual property, ownership and future use — especially in a university or research environment. Even if you do not want to commercialize your work yourself, you may still be part of what happens next.

When Publishing Is the Right Choice

Publishing your invention can be the right decision when your primary goal is scientific impact, recognition, or contributing to knowledge. In academic environments, publishing is often the default path, driven by incentives such as visibility, citations and career progression.

In practice, this situation can arise when key people move on, when there is no clear commercial path, or when the effort required to build a company outweighs the expected return.

Why “Doing Nothing” Is Often Not Neutral

Choosing not to actively commercialize an invention does not necessarily mean that nothing will happen. Universities and research institutes often have technology transfer offices (TTOs) that evaluate whether an invention can be protected and licensed.

If a patent is pursued, you may be asked to delay publication and remain involved in the process. Your knowledge of the underlying technology makes you difficult to replace, even if you are not personally interested in building a company.

You May Still Be Involved — Even If You Step Back

Even when you decide not to commercialize, your role does not always disappear. If others continue developing the invention — through licensing or a startup — your expertise may still be required. In practice, this can mean ongoing involvement in technical discussions, development decisions or intellectual property processes.

In other words, stepping away from the business side does not always mean stepping away completely. In practice, inventors are often asked to stay involved long after the initial discovery, simply because they are the only ones who fully understand the technology.

The Trade-Off: Impact vs Control

Publishing your invention maximizes accessibility and can accelerate impact, but it also means giving up control over how the invention is used and developed. Once knowledge is public, it cannot be made exclusive again.

This trade-off is closely related to intellectual property. In many cases, public disclosure affects whether an invention can still be protected.

A Deliberate Choice, Not a Default

Publishing should not be seen as the “easy” or passive option. It is a deliberate strategic choice that fits certain goals and environments, but not others.

Understanding what you gain — and what you give up — helps you decide whether this path fits your situation, or whether one of the other strategies is more appropriate.

About Siert Bruins

Siert Bruins, PhD

Hello! I'm Siert Bruins, a Dutch entrepreneur and founder of Life2Ledger B.V. . Trained as a Medical Biologist, I hold a PhD in Clinical Diagnostics from the University of Groningen and have over two decades of hands-on experience in innovation at the intersection of universities, hospitals and technology-driven companies.

Throughout my career, I have (co)-founded several life science startups and helped researchers, inventors, and early-stage founders transform their ideas into prototypes, patents, partnerships, and funded projects. My work spans medical device development, clinical validation, startup strategy, and technology transfer. I've guided innovations from the initial sketch to licensing agreements and investment negotiations.

Since 2009, I've run the Dutch version of this site. I launched to provide founders worldwide with practical, experience-based guidance on inventions, patents, valuation and raising startup capital. Today, in Life2Ledger, I also focus on blockchain-based data validation for AI in healthcare — Specifically: how can you be sure that your AI is trained and validated on the correct data, and that this data truly comes from the patient and the device you think it does?

The content on this site is based on my own experience with real startups — real negotiations, real decisions, and real outcomes. I use tools to support the writing process, but the insights, structure, and conclusions are my own. This is not generic content, but a reflection of what actually happens behind the scenes.

Want to connect? Visit my LinkedIn or follow me on X. Have questions about your startup strategy or patents? Reach out and I'll share practical insights from real-world experience.